Roivant Sciences Ltd (ROIV) FinancialsROIVRoivant Sciences Ltd

Evaluating the bottom line, Roivant Sciences Ltd maintains a gross margin of 80.31%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -22460.82%, while the net margin is -20152.98%. These profitability ratios, combined with a Return on Equity (ROE) of -6.21%, provide a clear picture of how effectively ROIV converts its operational activities into shareholder value.

In the context of the broader market, ROIV competes directly with industry leaders such as INCY and INSM. With a market capitalization of $26.15B, it holds a significant position in the sector. When comparing efficiency, ROIV's gross margin of 80.31% stands against INCY's 93.73% and INSM's 83.71%. Such benchmarking helps identify whether Roivant Sciences Ltd is trading at a premium or discount relative to its financial performance.

Roivant's revenue has shown volatility, with Q1 2026 revenue at $1.44 million, down 33.6% year-over-year. However, the recent FDA approval could lead to revenue growth in the upcoming quarters.